1. Background
Cancer is one of the major health problems affecting the world population, with high incidence and mortality. It has been estimated that 9.6 million people died from cancer in 2017 and that every sixth death in the world is due to it, making it the second leading cause of death after cardiovascular disease
[1]. Although significant advances have been achieved in cancer treatment during recent years, aggressive tumors such as those in the lung, breast, and pancreas are still inducing significant low survival of patients suggesting many efforts to be spent on improving the patient’s outcome
[2].
Every year, about 1.5 million people in the USA and 300,000 people in the UK
[3] are diagnosed with cancer. Cancer therapy and diagnosis remain the major problem in the world. In fact, a correct diagnosis is crucial for the accurate and effective treatment, because all tumors need for specific treatments such as the surgery, radiotherapy, and chemotherapy. However, to date the main problems of oncologists are the correct identification of the type of cancer, as well as the identification of the right pharmacological dose that provides the maximum therapeutic effect with the minimum toxicity
[4]. In addition, there is no single treatment for the several types of cancer and each treatment has advantages and disadvantages, which often affect the patient’s quality of life
[5]. Most chemotherapy drugs affect not only cancer cells but also healthy cells causing many of the symptoms related to the chemotherapy patients, including vomiting, hair loss, pale skin, etc.
[6]. In this context, diagnostic approaches and chemotherapeutic delivery based on nanotechnologies, such as nanoparticles (NPs), could be promising candidates for the new era of cancer research.
In recent decades, nanotechnology dominates most of the frontier research in many fields including biomedicine
[7], molecular diagnostic
[8], pharmaceutic
[9], optoelectronic
[10], and environmental care
[11]. Among the nanosystems, nanoparticles (NPs) are the most exploited. They are structures ranging from 1 to 100 nm in size that give rise to peculiar physical-chemical properties distinguished for many purposes. In the biomedical field, NPs are widely exploited for bioimaging
[12], drug delivery systems
[13], therapeutic agents for photodynamic (PDT)
[14], photothermal therapy (PTT)
[15], regenerative medicine
[16][17], smart biomaterials
[18], and sensing
[19]. Metal nanoparticles (MNPs) are the most studied, especially noble metal NPs, including Gold (AuNPs)
[20], Silver (AgNPs)
[21], Platinum (PtNPs)
[22] and Palladium (PdNPs)
[23]. Also, polymeric
[24] and lipids
[25] NPs, liposomes
[26], and nanohybrids represent other members of this large family.
Recently great attention has been paid to carbon-based nanomaterials such as Carbon Dots (CDs), fullerenes, Carbon nanotubes (CNTs) and Graphene Quantum Dots (GQD) that have attracted significant interest over recent years due to their excellent electrical conductivity and luminescence with broadband optical absorption and photostability, high chemical stability, low toxicity and great biocompatibility
[27].
In particular, CDs are featured by a graphitic core mainly constituted of sp
2 or sp
3 carbon and size ranging from less than 20 nm to up 60 nm
[28]. Synthetic methods for the preparation of CDs are based on two main approaches: top-down and bottom-up. In the former, CDs are obtained by breaking large carbon materials through laser ablation, acid oxidation, ultrasonic/electrochemical or hydrothermal/solvothermal exfoliation, arc discharge methods. In the bottom-up approaches, the nanostructures are prepared by carbonization of molecular precursors via microwave, hydrothermal, and thermal pyrolysis methods
[29].
Quantum confinement and surface state governs the CDs properties
[30] and they can be tuned by the synthetic strategy using different precursors or methods
[31][32]. Actually, CDs can be designed to exhibit various functional groups including amine, carboxyl, carbonyl, hydroxyl, ether, epoxy, and heteroatoms acting also as chemical groups to graft additional materials including organic, polymeric, and biological systems. The variegated design capability to obtain several size and surface functional groups confers to these systems the possibility to modulate their chemical-physical properties, particularly the photoluminescence (PL) that exhibits a wide range of emission wavelengths as function on both size (quantum effect), surface states and groups. All these variegated properties make CDs very appealing materials in cancer application with multiple use from bioimaging to nano-carriers for drug delivery systems and promising agents for photodynamic (PDT) and photothermal therapy (PTT).
3. CDs for Bioimaging
The excellent features of CDs, such as good biocompatibility and penetrability, low toxicity, weak interactions with proteins, resistance to photobleaching, easy clearance, low cost, and easy preparation, make them a useful tool for fluorescence labeling and imaging for diagnostic applications. This section will report some studies on CDs bioimaging capabilities both in vitro and in vivo.
In the last decade, CDs demonstrated a great potential for in vitro and in vivo imaging due to their strong emission fluorescence and low cytotoxicity. In fact, due to their physical-chemical properties and size, CDs can easily penetrate biological membranes and accumulate in cell cytosol or nucleus, thus functioning as a fluorescent probe ().
Figure 2. Illustration of CDs cellular internalization for bioimaging. Left part: sketch of a cell depicting CDs penetrating the cell membrane and accumulating in the cytosol (gray circles on the left); right part: sketch of representative fluorescent green staining by intracellular CDs (cell nuclei in the image are stained with DAPI (blue)).
Most dyes used for fluorescence microscopy require cell fixation, and only a few are available for living cell imaging. Hua et al.
[66] prepared fluorescent CDs, using a simple one-step hydrothermal treatment with the carbon sources of m-phenylenediamine and L-cysteine that can realize high-quality nucleolus imaging for not only fixed cells but also in living cells, demonstrating that these CDs possess superior properties compared with the only commercially available dye SYTO RNASelect. Ding et al.
[67] incubated HeLa cells (human cervical cancer cell lines) with CDs at high concentrations (up to 5 mg/mL) for 24 h, observing both a low cytotoxic effect and an uptake only into the cytoplasm with a yellow fluorescence. Jiang group’s
[68] synthesized three red, green, and blue (RGB) PL CDs and evaluated both their cytocompatibility and cell imaging. Their results showed over 90% cell viability in MCF-7 cells (human breast cancer cell line) incubated for 24 h with each of the three CDs, at concentrations from 10–50 µg/mL, and that living cells, acquired with a confocal microscope (excitation at 405 nm), fluoresced mainly in the cytoplasm, suggesting that the CDs are able to penetrate the cell membrane and enter cells. In another study, Li et al.
[69] demonstrated that C-dots are biocompatible and not cytotoxic with HeLa, SMMC-7721 (human hepatocellular carcinoma cells) and HEK 293 8-Human Embryonic Kidney cells) cell lines, in concentrations up to 500 μg/mL, and that they enter into cells and are mainly confined in lysosome/endosome. Zhang et al.
[70] showed that CDs prepared from polydopamine (PDA-FONs), with a concentration up to 160 mg mL
−1, were highly biocompatible with mouse embryonic fibroblast NIH-3T3 cells (cell viability > 90%), and bright green and yellow fluorescence were mainly located in the cytoplasm. Chen et al.
[71] displayed that CDs derived from carbonizing sucrose with oil acid (average 1.84 nm in size) easily penetrated the 16HBE (human bronchial epithelial cell line) but did not enter the nuclei, emitting green fluorescence around the cell membrane and cytoplasm.
Other researchers reported that CDs obtained from natural products (orange juice) did not show any cytotoxicity and were efficiently taken up by the cells (L929 and MG-63) upon incubation, exhibiting blue and green fluorescence in the cytoplasm, but not in the nuclei
[72].
In addition to in vitro studies, several researchers recently evaluated the possibility of using fluorescent CDs in vivo for biomedical applications. For example, Jiang et al.
[73] reported that Fluorine and Nitrogen-doped CDs (N-CDs-F), UV-Vis-NIR full-range responsive, incubated with HepG2 (human liver cancer cell line) and HeLa cells exhibit high cytocompatibility (cell viability >80%) and rapid cellular uptake in both cytoplasm and nucleus, localizing in the nucleolar region. Furthermore, they showed that N-CDs-F injected intraperitoneally into mice, at the concentration of 1 mg/mL, are able to penetrate deep tissue and so can be used for in vivo imaging. Yang et al.
[74] demonstrated, for the first time that CDs maintain a strong fluorescence in vivo after subcutaneous, intradermal, and intravenous injection, as well as being highly biocompatible and non-toxic. Huang et al.
[75] evaluated the effects of three fluorescent CDs injection ways (intravenous, intramuscular, and subcutaneous) on blood circulation, biodistribution, urine clearance, and passive tumor uptake, by using both near infrared fluorescence (NIRF) and positron emission tomography (PET) imaging techniques. They suggested that the injection method influences the rate of blood and urine clearance, the biodistribution of CDs in main organs and tissues, and cancer uptake over time. They also demonstrate that CDs are efficiently and rapidly uptake by the tumor when administered subcutaneously. In another study, Tao’s group
[76] characterized the biodistribution of radiolabeled, photoluminescent CDs and demonstrated for the first time that they could be used for in vivo NIRF imaging. Their results suggested that CDs were slowly eliminated via the renal and fecal ways without any obvious toxic effects on animals. Licciardello et al.
[77] investigated the CDs’ biodistribution and uptake in vivo through radioelement labeling and positron emission tomography (PET). Their study showed that the rapid renal clearance, biodistribution, and pharmacokinetic properties of CDs are strongly influenced by their surface charge, positive Zeta potentials, and hydrophilicity. More in detail, they demonstrated that particles with positive Zeta potentials accumulate in the liver and intestine while neutral/zwitterionic particles are rapidly cleared via the renal pathway with no significant liver uptake. The study also highlights how particle toxicity is associated with the amount of surface amine groups, as well as the possible presence of surfactant contamination traces after the CDs’ synthesis and purification. In summary, these in vitro and in vivo findings open promising scenarios for the fluorescent CDs application as tools for imaging in cancer diagnosis.
4. CDs for Cancer Diagnosis
The high sensitivity coupled by both the temporal and spatial resolution of fluorescence imaging make CDs one of the most promising candidates in cell target sensing and cell imaging
[78]. Recently, several research groups showed that CDs with specific cell targets are able to recognize tumor cells selectively. Song et al.
[79] produced CDs conjugated with folic acid (FA) (C-dots-FA) to discriminate folate receptor (FR)-positive cancer cells from normal cells (FR-negative) by culturing and analyzing a mixture of NIH-3T3 and HeLa cells. They observed that after the incubation of the cell mixture with C-dots-FA for 6 h, only HeLa cells emitted bright fluorescence, whereas NIH-3T3 cells did not, indicating that the C-dots-FA are selective only for FR-positive cancerous cells. Lee et al.
[80] developed CDs conjugated with maleimide-terminated TTA1 aptamer (TTA1–CDs), highly expressed in HeLa and C6 (rat glioma cell line) but not in normal healthy CHO cells (Chinese hamster ovary cell line), and found that the incubation of the TTA1–CDs showed a strong fluorescence, selectively along cancer cell membranes and only a little uptake in normal cells. Zhang et al.
[81] developed green luminescent CDs conjugated with FA (FA-CDs) and showed that the FA-CDs were able to selectively identify cancer cells within a mixture of HepG2 and PC12, displaying a bright green fluorescence, after 2 h of incubation, only in HepG2 cells. In another study, Li et al.
[82] reported a new targeting tumor therapy technology based on autophagy regulation by combining the biocompatible N-doped carbon dots (N-CDs) and folic acid (FA) (FN-CDs). Their results showed that FN-CDs possess a wide range of high-targeted-ability (26 types of tumor cell lines) and affect the cellular metabolism leading to autophagy. Bhunia et al.
[83] functionalized fluorescent CDs with TAT peptide or folate and incubated them with FR-positive (cancerous) and FR-negative (normal) cells, finding that TAT functionalization enhanced cell labeling and uptake and that folate selectively tagged tumor cells, which have folate receptors.